<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">thealth</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение Таджикистана</journal-title><trans-title-group xml:lang="en"><trans-title>Health care of Tajikistan</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0514-2415</issn><publisher><publisher-name>Редакция журнала «Здравоохранение Таджикистана»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52888/0514-2515-2021-350-33-40</article-id><article-id custom-type="elpub" pub-id-type="custom">thealth-259</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Вакцинацинация пентивалентной АКДС и АДС вакциной здоровых и часто болеющих детей</article-title><trans-title-group xml:lang="en"><trans-title>Vaccination of pentivalent, DTP, ADS vaccine for healthy and frequently sick children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамаджанова</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamadzhanova</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамаджанова Гульнора Сидикжановна – к.м.н., доцент, заведующая кафедрой детских болезней №1</p></bio><bio xml:lang="en"><p>Mamadzhanova Gulnora Sidikzhanovna - сandidate of Medical Sciences, Associate Professor, Head</p></bio><email xlink:type="simple">gulnora.mamadjanova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Умарова</surname><given-names>З. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Umarova</surname><given-names>Z. K.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саидмурадова</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Saidmuradova</surname><given-names>G. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра детских болезней № 1, ГОУ «ТГМУ им. Абуали ибни Сино»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>Department of childhood diseases №1, SEI «Avicenna Tajik State Medical University», Dushanbe, Republic of Tajikistan</institution><country>Tajikistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кафедра семейной медицины № 2, ГОУ «ТГМУ им. Абуали ибни Сино»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>Department of family medicine №2, SEI «Avicenna Tajik State Medical University», Dushanbe, Republic of Tajikistan</institution><country>Tajikistan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кафедра детских инфекций, ГОУ «ТГМУ им. Абуали ибни Сино»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>Department of childhood infections, SEI «Avicenna Tajik State Medical University», Dushanbe, Republic of Tajikistan</institution><country>Tajikistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2021</year></pub-date><volume>0</volume><issue>3</issue><fpage>33</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мамаджанова Г.С., Умарова З.К., Саидмурадова Г.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Мамаджанова Г.С., Умарова З.К., Саидмурадова Г.М.</copyright-holder><copyright-holder xml:lang="en">Mamadzhanova G.S., Umarova Z.K., Saidmuradova G.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zdrav.tj/jour/article/view/259">https://www.zdrav.tj/jour/article/view/259</self-uri><abstract><p>Цель исследования. Изучить вакцинированных здоровых и часто болеющих детей на формирование противодифтерийного иммунитета.Материалы и методы исследования. Под нашим наблюдением было 50 практически здоровых и 92 часто болеющих детей. Всем детям проводилась вакцинация трехкратно пентавалентной вакциной, а также ревакцинация АКДС и АДС. Определяли формирование специфического противодифтерийного иммунитета через 6 месяцев, 1 год и 5 лет. Интерпретировали результат по окончательному значению оптической плотности уровни защиты: базовая -0,01 до 0,1; полная защита - &gt;0,1; долгосрочная защита - &gt;1,0.Результаты исследования их обсуждение. Через 6 месяцев напряжённость поствакцинального иммунитета как у здоровых, так и у больных детей составили высокий процент: полная (&gt;0,1) (45,8%) и базовая защита (0,01 до 0,1) (31,0%). Статистическая значимость снизилась через год: полная защита (45,8% против 12,1%, p&lt;0,001), и повысилась отсутствие защиты (2,6% против 55,7%, p&lt;0,001), что указывало на выработку нестойкого иммунитета в связи, с чем была проведена ревакцинация АКДС и АДС. Через 5 лет после ревакцинации, специфический иммунитет имел тенденцию к нарастанию как у здоровых детей, так и у больных.Заключение. Для создания стойкого и продолжительного иммунитета при использовании «убитых» вакцин и анатоксинов необходимы ревакцинирующие прививки через различные сроки после курса вакцинации часто болеющим детям, на что указывают данные базовой и полной защиты.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the formation of anti-diphtheria post-vaccination immunity in practically healthy, and frequently sick children vaccinated with pentavalent, ADTP, and ADT vaccine.Material and methods. We observed 50 practically healthy and 92 frequently sick children. All children were vaccinated three times with a pentavalent vaccine, as well as revaccination with ADTP and ADT. The formation of specific anti-diphtheria immunity was detected for all children after 6 months, after 1 year, and after 5 years. The results were interpreted according to the final value of the optical density levels of protection: basic from -0,01 to 0,1; full protection -&gt; 0.1; long-term protection -&gt; 1.0.Results and discussion. After 6 months the intensity of post-vaccination immunity in both practically healthy and frequently sick children was the highest: full protection (&gt; 0.1) (45,8%), basic protection (0,01 to 0,1) (31,0%). Statistical significance decreased after a year: full protection (45,8% versus 12,1%, p &lt;0,001), and lack of protection increased (2,6% versus 55,7%, p &lt;0,001), which indicated to the development of unstable immunity, therefore revaccination with ADTP and ADT vaccines were performed. 5 years after revaccination specific immunity tended to increase in both healthy and often-ill children.Conclusion. To create stable and long-term immunity when using “killed” vaccines and toxoids, revaccination vaccinations are required at various times after the course of vaccination for frequently ill children, as indicated by the data of basic and complete protection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>дифтерия</kwd><kwd>специфический иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>children</kwd><kwd>diphtheria specific immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гречуха Т.А. Опыт применения АКДС- гексавакцины на базе отделения вакцинопрофилактики детей с отклонения в состоянии здоровья / Т.А. Гречуха // ФГБНУ Научный центр здоровья детей. Педиатрическая фармакология. - 2014. -№11(4). - С. 78-83</mixed-citation><mixed-citation xml:lang="en">Grechukha T.A. Opyt primeneniya AKDS- geksavaktsiny na baze otdeleniya vaktsinoprofilaktiki detey s otkloneniya v sostoyanii zdorovya [Experience of using DPT-hexavaccine at the Department of Vaccine Prophylaxis for Children with Disabilities]. Nauchnyy tsentr zdorovya detey. Pediatricheskaya farmakologiya - Scientific Center for Children’s Health. Pediatric Pharmacology, 2014, Vol. 11, No. 4, pp. 78-83.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Додхоев Д.С. Аспекты иммунного статуса у детей с пневмонией на фоне перинатального поражения. / Д.С. Додхоев // Вестник Авиценны. - 2011. - №4. - С. 154-158.</mixed-citation><mixed-citation xml:lang="en">Dodkhoev D.S. Aspekty immunnogo statusa u detey s pnevmoniey na fone perinatalnogo porazheniya [Aspects of immune status in children with perinatal pneumonia]. Vestnik Avitsenny - Avicenna Bulletin, 2011, No. 4, pp. 154-158.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев М.Ю. Вспомогательная иммунотерапия у пациентов с иммунодефицитом и часто болеющих детей / М.Ю. Елисеев // Справочник поликлинического врача. - 2010. - № 9. - С.7-14.</mixed-citation><mixed-citation xml:lang="en">Eliseev M.Yu. Vspomogatelnaya immunoterapiya u patsientov s immunodefitsitom i chasto boleyushchikh detey [Complementary immunotherapy in immunodeficient patients and frequently ill children]. Spravochnik poliklinicheskogo vracha - Outpatient doctor’s guide, 2010, No. 9, pp. 7-14.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Икоев В.Н. Особенности изучения иммуногенности бактериальных вакцин в клинических исследованиях. / В.Н. Икоев // Биопрепараты. - 2013. - №1. - С. 6-11.</mixed-citation><mixed-citation xml:lang="en">Ikoev V.N. Osobennosti izucheniya immunogennosti bakterialnykh vaktsin v klinicheskikh issledovaniyakh [Peculiarities of studying the immunogenicity of bacterial vaccines in clinical trials]. Biopreparaty - Biologicals, 2013, No. 1, pp. 6-11.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Коровина H.A, Заплатников А.Л, Фисенко Ю.Ю. Оптимизация вакцинации часто болеющих детей. / H.A Коровина, А.Л Заплатников, Ю.Ю. Фисенко // Вопросы современной педиатрии. - 2015. - №4. - С. 92-96.</mixed-citation><mixed-citation xml:lang="en">Korovina H.A., Zaplatnikov A.L., Fisenko Yu.Yu. Optimizatsiya vaktsinatsii chasto boleyushchikh detey [Optimization of vaccination of frequently ill children]. Voprosy sovremennoy pediatrii – Questions of modern pediatrics, 2015, No. 4, pp. 92-96.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Малахов А.Б. Основные направления совершенствования вакцинопрофилактики управляемых инфекций у детей и подростков / А.Б. Малахов С.М. Харит // Педиатрия. – 2010 - №5(56). – С. 32-38.</mixed-citation><mixed-citation xml:lang="en">Malakhov A.B. Osnovnye napravleniya sovershenstvovaniya vaktsinoprofilaktiki upravlyaemykh infektsiy u detey i podrostkov [Main directions of improvement of vaccine prophylaxis of controllable infections in children and adolescents]. Pediatriya – Pediatrics, 2010, Vol. 5, No. 56, pp. 32-38.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Назарова ЕВ. Аллергические реакции на вакцины. / Е.В. Назарова // Эффективная фармакотерапия. - 2016. - №24. - С. 10-13.</mixed-citation><mixed-citation xml:lang="en">Nazarova E.V. Allergicheskie reaktsii na vaktsiny [Аллергические реакции на вакцины]. Effektivnaya farmakoterapiya - Effective pharmacotherapy, 2016, No. 24, pp. 10-13.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Рахимова У.Х. Особенности клинико-иммуно-логического течения атопического дерматита у детей / У.Х. Рахимова // Вестник Авиценны. - 2015. - №3(64). - С. 64-69.</mixed-citation><mixed-citation xml:lang="en">Rakhimova U.Kh. Osobennosti kliniko-immunologicheskogo techeniya atopicheskogo dermatita u detey [Peculiarities of the clinical and immunological course of atopic dermatitis in children]. Vestnik Avitsenny – Avicenna Bulletin, 2015, Vol. 3, No. 64, pp. 64-69.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Сарбасова Ж.О. Часто болеющие дети / Ж.О. Сарбасова // Здоровье и болезни. - 2012. - №5(107). - С. 111-114.</mixed-citation><mixed-citation xml:lang="en">Sarbasova Zh.O. Chasto boleyushchie deti [Frequently ill children]. Zdorove i bolezni - Health and diseases, 2012, Vol. 5, No. 107, pp. 111-114.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bar-On E.S. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza B (HIB). Cochrane Acute Respiratory Infections Group, 2012, No. 10, рр. 1002-1005.</mixed-citation><mixed-citation xml:lang="en">Bar-On E.S. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza B (HIB). Cochrane Acute Respiratory Infections Group, 2012, No. 10, рр. 1002-1005.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bitraguntaa S. Safety and immunogenicity of single dose of tetanus–diphtheria (Td) vaccine among non/ partially immune children against diphtheria and/or tetanus, Hyderabad, India, 2007. Vaccine Journal, 2010, Vol. 28, pp. 5934-5938.</mixed-citation><mixed-citation xml:lang="en">Bitraguntaa S. Safety and immunogenicity of single dose of tetanus–diphtheria (Td) vaccine among non/ partially immune children against diphtheria and/or tetanus, Hyderabad, India, 2007. Vaccine Journal, 2010, Vol. 28, pp. 5934-5938.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kattan J.D. Anaphylaxis to diphtheria, tetanus, pertussis vaccines among children with cow’s milk allergy. Journal of Allergy and Clinical Immunology, 2011 Vol. 128, No. 1, pp. 215-218.</mixed-citation><mixed-citation xml:lang="en">Kattan J.D. Anaphylaxis to diphtheria, tetanus, pertussis vaccines among children with cow’s milk allergy. Journal of Allergy and Clinical Immunology, 2011 Vol. 128, No. 1, pp. 215-218.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kwon H.J. Assessment of Serologic Immunity to Diphtheria-Tetanus- Pertussis after Treatment of Korean Pediatric Hematology and Oncology Patients. Journal of Korean Medical Science, 2012, No. 27, pp. 78-83.</mixed-citation><mixed-citation xml:lang="en">Kwon H.J. Assessment of Serologic Immunity to Diphtheria-Tetanus- Pertussis after Treatment of Korean Pediatric Hematology and Oncology Patients. Journal of Korean Medical Science, 2012, No. 27, pp. 78-83.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kurugol Z., Midyat L., Turkog E. Immunity against diphtheria among children and adults in Izmir, Turkey. Vaccine Journal, 2011, No. 29, pp. 4341-4344.</mixed-citation><mixed-citation xml:lang="en">Kurugol Z., Midyat L., Turkog E. Immunity against diphtheria among children and adults in Izmir, Turkey. Vaccine Journal, 2011, No. 29, pp. 4341-4344.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson J.C. Adapting group sequential methods to observational postlicensure vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Journal of Epidemiology, 2013, Vol. 177, No. 2, pр. 131-141.</mixed-citation><mixed-citation xml:lang="en">Nelson J.C. Adapting group sequential methods to observational postlicensure vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Journal of Epidemiology, 2013, Vol. 177, No. 2, pр. 131-141.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma H. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwPHib vaccine. Vaccine Journal, 2013, No. 31, pр. 444-447.</mixed-citation><mixed-citation xml:lang="en">Sharma H. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwPHib vaccine. Vaccine Journal, 2013, No. 31, pр. 444-447.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma H. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants. Vaccine Journal, 2011, No. 29, pp. 2359-2364.</mixed-citation><mixed-citation xml:lang="en">Sharma H. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants. Vaccine Journal, 2011, No. 29, pp. 2359-2364.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Scheifele D.W., Ochnio J.J., Halperin S.A. Cellular Immunity as a Potential Cause of Local Reactions to Booster Vaccination with Diphtheria and Tetanus Toxoids and Acellular Pertussis Antigens. The Pediatric Infectious Disease Journal, 2012, Vol. 28, No. 11, pp. 985-989.</mixed-citation><mixed-citation xml:lang="en">Scheifele D.W., Ochnio J.J., Halperin S.A. Cellular Immunity as a Potential Cause of Local Reactions to Booster Vaccination with Diphtheria and Tetanus Toxoids and Acellular Pertussis Antigens. The Pediatric Infectious Disease Journal, 2012, Vol. 28, No. 11, pp. 985-989.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
